Climb Bio (CLYM) Other financing activities (2024 - 2026)
Climb Bio's (CLYM) quarterly Other financing activities came in at $5000.0 in Q1 2026, down 100.0% on a QoQ basis from $108.8 million in Q4 2024.
Analysis
Climb Bio (CLYM) Other financing activities (2024 - 2026) Analysis & Trends
Climb Bio (CLYM) has 2 years of Other financing activities data on file, last reported at $5000.0 in Q1 2026.
- Quarterly Other financing activities changed N/A year-over-year to $5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5000.0 (down 100.0% YoY) and the FY2024 annual result came in at $119.8 million, changed N/A from the prior year.
- Other financing activities eased to $5000.0 in Q1 2026, from $108.8 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $119.7 million in Q2 2024 to a low of $5000.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Climb Bio | 1.18 Bn | 1.18 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 103.36 Mn |
| Mar 31, 2026 | 5,000.00 |
| Dec 31, 2025 | 65,000.00 |
| Jun 30, 2024 | 119.75 Mn |